Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Oppenheimer Holdings issued their Q1 2018 EPS estimates for shares of Kura Oncology in a note issued to investors on Sunday. Oppenheimer Holdings analyst L. Cann forecasts that the company will post earnings of ($0.55) per share for the quarter. Oppenheimer Holdings also issued estimates for Kura Oncology’s Q2 2018 earnings at ($0.57) EPS, Q3 2018 earnings at ($0.76) EPS and Q4 2018 earnings at ($0.83) EPS.

Several other brokerages have also recently issued reports on KURA. Zacks Investment Research cut Kura Oncology from a “buy” rating to a “hold” rating in a report on Friday, September 29th. ValuEngine raised Kura Oncology from a “sell” rating to a “hold” rating in a report on Friday, September 8th. Citigroup Inc. set a $13.00 price objective on Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $18.00 price objective (up from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $16.00.

COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/brokers-set-expectations-for-kura-oncology-inc-s-q1-2018-earnings-kura/1673736.html. Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03.

A number of large investors have recently added to or reduced their stakes in KURA. State of Wisconsin Investment Board purchased a new stake in Kura Oncology during the 2nd quarter valued at $102,000. Oppenheimer & Co. Inc. raised its holdings in Kura Oncology by 14.7% during the 1st quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock valued at $110,000 after buying an additional 1,600 shares during the period. Rhumbline Advisers purchased a new stake in Kura Oncology during the 2nd quarter valued at $131,000. Nationwide Fund Advisors purchased a new stake in Kura Oncology during the 1st quarter valued at $136,000. Finally, New York State Common Retirement Fund purchased a new stake in Kura Oncology during the 2nd quarter valued at $142,000. Institutional investors own 40.56% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.